🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
9.38
-0.22 (-2.29%)
At close: Nov 18, 2026, 4:00 PM EST
9.24
-0.14 (-1.49%)
Pre-market: Nov 19, 2026, 4:01 AM EST

Bicara Therapeutics Statistics

Total Valuation

BCAX has a market cap or net worth of $622.71 million. The enterprise value is $181.25 million.

Market Cap622.71M
Enterprise Value 181.25M

Important Dates

The last earnings date was Monday, November 9, 2026, before market open.

Earnings Date Nov 9, 2026
Ex-Dividend Date n/a

Share Statistics

BCAX has 66.39 million shares outstanding. The number of shares has increased by 15.60% in one year.

Current Share Class 66.39M
Shares Outstanding 66.39M
Shares Change (YoY) +15.60%
Shares Change (QoQ) +0.66%
Owned by Insiders (%) 1.83%
Owned by Institutions (%) 76.98%
Float 36.94M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.52
P/TBV Ratio 1.52
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.81, with a Debt / Equity ratio of 0.00.

Current Ratio 8.81
Quick Ratio 8.63
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -54.24% and return on invested capital (ROIC) is -36.35%.

Return on Equity (ROE) -54.24%
Return on Assets (ROA) -33.47%
Return on Invested Capital (ROIC) -36.35%
Return on Capital Employed (ROCE) -57.89%
Weighted Average Cost of Capital (WACC) 2.38%
Revenue Per Employee n/a
Profits Per Employee -$2.14M
Employee Count103
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, BCAX has paid $221,000 in taxes.

Income Tax 221,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -37.67% in the last 52 weeks. The beta is -0.34, so BCAX's price volatility has been lower than the market average.

Beta (5Y) -0.34
52-Week Price Change -37.67%
50-Day Moving Average 16.00
200-Day Moving Average 20.73
Relative Strength Index (RSI) 31.77
Average Volume (20 Days) 2,302,838

Short Selling Information

The latest short interest is 9.86 million, so 14.85% of the outstanding shares have been sold short.

Short Interest 9.86M
Short Previous Month 10.30M
Short % of Shares Out 14.85%
Short % of Float 26.70%
Short Ratio (days to cover) 5.71

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -237.03M
Pretax Income -220.06M
Net Income -220.28M
EBITDA -236.83M
EBIT -237.03M
Earnings Per Share (EPS) -$3.49
Full Income Statement

Balance Sheet

The company has $442.35 million in cash and $880,000 in debt, with a net cash position of $441.47 million or $6.65 per share.

Cash & Cash Equivalents 442.35M
Total Debt 880,000
Net Cash 441.47M
Net Cash Per Share $6.65
Equity (Book Value) 409.41M
Book Value Per Share 6.17
Working Capital 400.18M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$161.73 million and capital expenditures -$1.02 million, giving a free cash flow of -$162.75 million.

Operating Cash Flow -161.73M
Capital Expenditures -1.02M
Depreciation & Amortization 191,000
Net Borrowing n/a
Free Cash Flow -162.75M
FCF Per Share -$2.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BCAX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -15.60%
Shareholder Yield -15.60%
Earnings Yield -37.23%
FCF Yield -26.14%

Analyst Forecast

The average price target for BCAX is $32.17, which is 242.96% higher than the current price. The consensus rating is "Buy".

Price Target $32.17
Price Target Difference 242.96%
Analyst Consensus Buy
Analyst Count 14
Revenue Growth Forecast (3Y) n/a
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1